Prescription drug prices paid under federal programs analyses, differences, factors
Prescription drug prices paid under federal programs: analyses, differences, factors
Gespeichert in:
Bibliographische Detailangaben
Format: Elektronisch E-Book
Sprache:English
Veröffentlicht: New York Nova Science Publishers [2014]
Schriftenreihe:Health care in transition series
Schlagworte:
Drugs / Prices
Health status indicators
Prescription pricing
MEDICAL / Pharmacology
Medical care, Cost of
Prescription pricing / Government policy
Medizin
Politik
Prescription pricing > United States
Medical care, Cost of > United States
Prescription pricing > Government policy > United States
USA
Beschreibung:Includes index
PRESCRIPTION DRUG PRICES PAID UNDER FEDERAL PROGRAMS: ANALYSES, DIFFERENCES, FACTORS; PRESCRIPTION DRUG PRICES PAID UNDER FEDERAL PROGRAMS: ANALYSES, DIFFERENCES, FACTORS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: PRESCRIPTION DRUGS: COMPARISON OF DOD, MEDICAID, AND MEDICARE PART DRETAIL REIMBURSEMENT PRICES; WHY GAO DID THIS STUDY; WHAT GAO FOUND; ABBREVIATIONS; BACKGROUND; MEDICAID PAID LOWER NET PRICES THAN DOD ANDMEDICARE PART D, LARGELY DUE TO DIFFERENCES INPOST-PURCHASE PRICE ADJUSTMENTS; AGENCY COMMENTS; APPENDIX I: SCOPE AND METHODOLOGY.
Chapter 2: PRESCRIPTION DRUGS: COMPARISON OF DOD AND VADIRECT PURCHASE PRICESWHY GAO DID THIS STUDY; WHAT GAO FOUND; ABBREVIATIONS; BACKGROUND; DOD PAID A HIGHER AVERAGE DIRECT PURCHASEPRICE THAN VA ACROSS THE ENTIRE SAMPLE BUT PAIDLESS THAN VA FOR BRAND-NAME DRUGS; CONCLUDING OBSERVATIONS; AGENCY COMMENTS AND OUR EVALUATION; APPENDIX I: SCOPE AND METHODOLOGY; APPENDIX II: RELATIVE PRICES PAID BY DOD AND VAFOR THE 83 DRUGS IN THE DIRECT PURCHASE SAMPLE; Chapter 3: PRESCRIPTION DRUGS: OVERVIEW OF APPROACHES TO CONTROL PRESCRIPTION DRUG SPENDING IN FEDERAL PROGRAMS; WHY GAO DID THIS STUDY.
WHAT GAO FOUNDBACKGROUND; FEHBP USES COMPETITION BETWEEN HEALTH PLANSTO CONTROL PRESCRIPTION DRUG COSTS; OTHER FEDERAL PROGRAMS USE A RANGEOF APPROACHES TO CONTROL PRESCRIPTIONDRUG SPENDING; Chapter 4: MEDICAID PRESCRIPTION DRUGS:CMS SHOULD IMPLEMENT REVISEDFEDERAL UPPER LIMITS AND MONITORTHEIR RELATIONSHIP TO RETAILPHARMACY ACQUISITION COSTS*; WHY GAO DID THIS STUDY; WHAT GAO RECOMMENDS; WHAT GAO FOUND; ABBREVIATIONS; BACKGROUND; CMS DEVELOPS NADACS BY SURVEYING RETAILCOMMUNITY PHARMACIES FOR INVOICE DATA ONACTUAL ACQUISITION COSTS.
First quarter 2013 ppaca-based fulswere nearly equal to nadacs across alldrugs in aggregate, but varied greatlyfor individual drugsconclusion; recommendation for executive action; agency comments and our evaluation; appendix i.methodology for comparingfederal upper limits to national averagedrug acquisition costs; appendix ii. comparison of federalupper limits to national average drugacquisition costs, top 50medicaidexpenditure drugs; appendix iii. comparison of federal upper limitsto national average drug acquisition costs, top50medicaid utilization drugs
APPENDIX IV. 3-MONTH ROLLING AVERAGE FEDERALUPPER LIMITS COMPARED WITH NATIONAL AVERAGEDRUG ACQUISITION COSTSBlank Page; INDEX.
In 2011, federal spending for prescription drugs by DOD, Medicaid, and Medicare Part D totaled 71.2 billion-representing about 85 percent of all federal prescription drug expenditures-for about 114.4 million beneficiaries. Each program reimbursed retail pharmacies for outpatient prescriptions filled at these pharmacies by their beneficiaries. This book compares retail reimbursement prices paid by DOD, Medicaid, and Medicare Part D for a sample of prescription drugs and describes factors affecting these prices. It also discusses approaches to control prescription drug spending in federal progra
ISBN:9781634634151
1634634152

Es ist kein Print-Exemplar vorhanden.

Fernleihe Bestellen Achtung: Nicht im THWS-Bestand!

Ähnliche Einträge